アブストラクト
| Title | 膵癌に対する術前化学療法 |
|---|---|
| Subtitle | 特集 胆膵専門外来〜エキスパートによる至極の指南書〜 IV. 胆膵がん外来 |
| Authors | 石井重登1), 壁村大至1), 太田寛人1), 牛尾真子1), 福間泰斗1), 高橋翔1), 鈴木彬実1), 伊藤光一1), 冨嶋亨1), 藤澤聡郎1), 吉岡龍二2), 齋浦明夫2), 伊佐山浩通1) |
| Authors (kana) | |
| Organization | 1)順天堂大学大学院医学研究科消化器内科学, 2)順天堂大学大学院医学研究科肝・胆・膵外科学 |
| Journal | 胆と膵 |
| Volume | 43 |
| Number | 特別 |
| Page | 1407-1413 |
| Year/Month | 2022 / 11 |
| Article | 報告 |
| Publisher | 医学図書出版 |
| Abstract | 「要約」 : 膵癌は予後不良の難治性がんの一つである. 切除可能と診断されたとしても潜在的な遠隔転移を有していることが多く, 治療成績の向上を目的とした化学療法を主体とした術前治療および術後補助化学療法の有用性が多く報告されてきている. 本邦においてはPrep-02/JSAP-05試験の結果をもとに切除可能膵癌に対して術前化学療法としてゲムシタビン+S-1を2コース施行することが一般的となった. 切除可能境界膵癌に対する術前治療, 切除不能局所進行膵癌におけるコンバージョン切除の基準においては十分なエビデンスを有する治療戦略は定まっておらず, 各施設が独自の戦略を立てているのが実情である. 一方, 術後補助化学療法としてはJASPAC01試験の結果をもとに半年間のS-1内服が標準治療となった. しかし, 治癒切除が得られたとしても術後早期再発を認める症例も多く経験し, 手術の恩恵を十分に得られていない症例も存在しており, まだ検討課題も多く, さらなるエビデンスの構築が求められる. |
| Practice | 臨床医学：内科系 |
| Keywords | 膵癌, 術前治療, 術後補助化学療法, 早期再発 |
- 全文ダウンロード： 従量制、基本料金制の方共に1,023円(税込) です。
参考文献
- 1) 日本膵臓学会編 : 膵癌取り扱い規約第7版. 金原出版, 2016.
- 2) Ye C, Sadula A, Ren S et al. : The prognostic value of CA19-9 response after neoadjuvant therapy in patients with pancreatic cancer : a systematic review and pooled analysis. Cancer Chemother Pharmacol 86 : 731-740, 2020.
- 3) Hartwig W, Strobel O, Hinz U, et al. : CA19-9 in potentially resectable pancreatic cancer : perspective to adjust surgical and perioperative therapy. Ann Surg Oncol 20 : 2188-2196, 2013.
- 4) Isaji S, Mizuno S, Windsor JA, et al. : International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017. Pancreatology 18 : 2-11, 2018.
- 5) Oba A, Inoue Y, Ono Y, et al. : Staging laparoscopy for pancreatic cancer using intraoperative ultraso-nography and fluorescence imaging : the SLING trial. Br J Surg 108 : 115-118, 2021.
残りの22件を表示する
- 6) Golcher H, Brunner TB, Witzigmann H, et al. : Neoad-juvant chemoradiation therapy with gemcitabine/cisplatin and surgery versus immediate surgery in resectable pancreatic cancer : results of the first pro-spective randomized phase II trial. Strahlenther Onkol 191 : 7-16, 2015.
- 7) Casadei R, Di Marco M, Ricci C et al. : Neoadjuvant chemoradiotherapy and surgery versus surgery alone in resectable pancreatic cancer : a single-cen-ter prospective, randomized, controlled trial which failed to achieve accrual targets. J Gastrointest Surg 19 : 1802-1812, 2015.
- 8) Motoi F, Kosuge T, Ueno H, et al. : Randomized phase II/III trial of neoadjuvant chemotherapy with gem-citabine and S-1 versus upfront surgery for resect-able pancreatic cancer(Prep-02/JSAP05). Jpn J Clin Oncol 49 : 190-194, 2019.
- 9) 日本膵臓学会編 : 膵癌診療ガイドライン2022. 金原出版, 2022.
- 10) Kato H, Usui M, Isaji S et al. : Clinical features and treatment outcome of borderline resectable pancre-atic head/body cancer : a multi-institutional survey by the Japanese Society of Pancreatic Surgery. J Hepatobiliary Pancreat Sci 20 : 601-610, 2013.
- 11) Jang JY, Han Y, Lee H, et al. : Oncological benefits of neoadjuvant chemoradiation with gemcitabine versus upfront surgery in patients with borderline resect-able pancreatic cancer : a prospective, randomized, open-label, multicenter phase 2/3 trial. Ann Surg 268 : 215-222, 2018.
- 12) Nagakawa Y, Sahara Y, Hosokawa Y, et al. : Clinical impact of neoadjuvant chemotherapy and chemora-diotherapy in borderline resectable pancreatic can-cer : analysis of 884 patients at facilities specializing in pancreatic surgery. Ann Surg Oncol 26 : 1629-1636, 2019.
- 13) Fujii T, Satoi S, Yamada S, et al. : Clinical benefits of neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreatic head : an observational study using inverse probability of treatment weighting. J Gastro-enterol 52 : 81-93, 2017.
- 14) Versteijne E, Vogel JA, Besselink MG, et al. : Meta-analysis comparing upfront surgery with neoadju-vant treatment in patients with resectable or border-line resectable pancreatic cancer. Br J Surg 105 : 946-958, 2018.
- 15) Ielpo B, Caruso R, Duran H, et al. : A comparative study of neoadjuvant treatment with gemcitabine plus nab-paclitaxel versus surgery first for pancre-atic adenocarcinoma. Surg Oncol 26 : 402-410, 2017.
- 16) Murakami Y, Uemura K, Sudo T et al. Survival impact of neoadjuvant gemcitabine plus S-1 chemotherapy for patients with borderline resectable pancreatic carcinoma with arterial contact. Cancer Chemother Pharmacol 79 : 37-47, 2017.
- 17) Strobel O, Berens V, Hinz U, et al. : Resection after neoadjuvant therapy for locally advanced, "unresect-able" pancreatic cancer. Surgery 152(3 Suppl1) : S33-S42, 2012.
- 18) Hackert T, Sachsenmaier M, Hinz U et al. : Locally advanced pancreatic cancer : neoadjuvant therapy with folfirinox results in resectability in 60% of the patients. Ann Surg 264 : 457-463, 2016.
- 19) Bednar F, Zenati MS, Steve J, et al. : Analysis of pre-dictors of resection and survival in locally advanced stage III pancreatic cancer : does the nature of che-motherapy regimen Influence outcomes? Ann Surg Oncol 24 : 1406-1413, 2017.
- 20) Marthey L, Sa-Cunha A, Blanc JF, et al. : FOLFIRI-NOX for locally advanced pancreatic adenocarci-noma : results of an AGEO multicenter prospective observational cohort. Ann Surg Oncol 22 : 295-301, 2015.
- 21) Suker M, Beumer BR, Sadot E et al. FOLFIRINOX for locally advanced pancreatic cancer : a systematic review and patient-level meta-analysis. Lancet Oncol 17 : 801-810, 2016.
- 22) Katz MH, Fleming JB, Bhosale P, et al. : Response of borderline resectable pancreatic cancer to neoadju-vant therapy is not reflected by radiographic indica-tors. Cancer 118 : 5749-5756, 2012.
- 23) Donahue TR, Isacoff WH, Hines OJ, et al. : Downstag-ing chemotherapy and alteration in the classic com-puted tomography/magnetic resonance imaging signs of vascular involvement in patients with pan-creaticobiliary malignant tumors : influence on patient selection for surgery. Arch Surg 146 : 836-43, 2011.
- 24) Satoi S, Yamaue H, Kato K, et al. : Role of adjuvant surgery for patients with initially unresectable pan-creatic cancer with a long-term favorable response to non-surgical anti-cancer treatments : results of a project study for pancreatic surgery by the Japanese Society of Hepato-Biliary-Pancreatic Surgery. J Hepatobiliary Pancreat Sci 20 : 590-600, 2013.
- 25) Tsai S, George B, Wittmann D et al. : Importance of normalization of CA19-9 levels following neoadju-vant therapy in patients with localized pancreatic cancer. Ann Surg 271 : 740-747, 2020.
- 26) Boone BA, Steve J, Zenati MS, et al. : Serum CA 19-9 response to neoadjuvant therapy is associated with outcome in pancreatic adenocarcinoma. Ann Surg Oncol 21 : 4351-4358, 2014.
- 27) Aoki S, Motoi F, Murakami Y, et al. : Decreased serum carbohydrate antigen 19-9 levels after neoad-juvant therapy predict a better prognosis for patients with pancreatic adenocarcinoma : a multicenter case-control study of 240 patients. BMC Cancer 19 : 252, 2019.
